ERBB2 and breast cancer: To date, several distinct BC phenotypes have been recognized, namely luminal A, luminal B, human epidermal growth factor 2 receptor (HER2)-positive, and triple-negative, based on the presence or absence of specific molecular targets, including estrogen receptors (ER), progesterone receptors, HER2, and Ki-67 antigen expression levels.